Handbook of Pharmaceutical Science and Technology Studies

Douglas, Conor M. W.; Geiger, Susi; Kleinhout-Vliek, Tineke; Martin, Paul; Wadmann, Sarah

Handbook of Pharmaceutical Science and Technology Studies

Edited by Conor M. W. Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah Wadmann

Abstract: This comprehensive Handbook examines innovation in the pharmaceutical sector using ideas drawn from the interdisciplinary field of science and technology studies (STS). Leading experts present diverse social science approaches to pharmaceuticals, consolidating existing research and providing an agenda for future research in this area.

Keywords: Pharmaceutical Innovation; Political Economy Of Pharmaceuticals; Alternative Innovation Models; Pharmaceutical Regulation And Governance; Pharmaceutical Markets; Science And Technology Studies; Global Health (search for similar items in EconPapers)
Date: 2026
ISBN: 9781035338443
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.elgaronline.com/doi/10.4337/9781035338450 (application/pdf)
Our link check indicates that this URL is bad, the error code is: 403 Forbidden

Chapters in this book:

Introduction to the Handbook of Pharmaceutical Science and Technology Studies: Conor M. W. Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah Wadmann
The production of pharmaceutical knowledge: Paul Martin
Myths about innovation in the pharmaceutical industry: Joel Lexchin
From bench to bedside and back again: Joshua R. Moon
Population-making in the regulatory arenas of clinical trials: Jakob Wested
The dynamics of “Orphanization” and the move towards precision medicine: Paul Martin, Andy Bartlett, Jin Ding, Matthew S. Hanchard and Eva Hilberg
How can innovation policy address “market failures” in the development of novel medicines?: Jin Ding, Michael M. Hopkins and Jorge Mestre-Ferrandiz
Social pharmaceutical innovation (SPIN): A sensitizing concept for challenges in rare diseases: Conor M. W. Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Wouter Boon, Claudio Cordovil Oliveira, Ellen Moors, Shir Grunebaum and Fernando Aith
The political economy of the manufacturing and production of pharmaceuticals: Conor M. W. Douglas
Vaccine nationalism beyond COVID-19: Prior dynamics and subsequent effects: Vesna Trifunović, Jan Hendriks and Stuart Blume
Peripheral vaccine promises in Latin America: Expectations, coalitions, and sovereignty: Gabriela Bortz, María Cecilia Sanmartin and Elize Massard da Fonseca
A world of generics: The manufacturing and circulation of generic medicines worldwide: Etienne Nouguez
Manufacturing and production of advanced therapies: A case of blurred boundaries: Michael Morrison, Isabel Briz Hernandez and Conor M. W. Douglas
Between activism and entrepreneurship: Challenging epistemic authority through pharmaceutical peer production: Bianca Jansky, Shane O’Donnell, Henriette Langstrup and Muireann Quigley
Drugged ecologies: The case of pharmaceutical pollution: Gergely Mohácsi
Pharmaceutical marketization: How markets in pharma are made and shaped: Susi Geiger
The financialization of the pharmaceutical industry: The case of Novo Nordisk's Wegovy: Joan Busfield
“The price that we pay is not the real price of the medicine”: How the pharmaceutical price architecture facilitates financial accumulation: Susi Geiger and Théo Bourgeron
Medical writing, the marketing playbook, and the pharmaceutical industry: Maud Bernisson, Willem Halffman and Sergio Sismondo
The work digital does in pharmaceutical markets: Gemma Milne and Mathias Møllebæk
Pharmaceuticals from and for the Global South: Jean-Paul Gaudillière and Fanny Chabrol
Regimes of pharmaceutical governance: Tineke Kleinhout-Vliek
Expedited pathways in drug regulation: Evidence, uncertainty, and acceleration in biomedical innovation: Mathias Møllebæk
From unmet medical needs to dilemmas of access to treatment: The case of rare diseases and orphan drugs: Carlos Novas
The (ill)logics of patient engagement in drug development and evaluation: Olga Zvonareva and Hadewych Honné
Preventing, detecting, and responding to falsified and substandard medicines: Raffaella Ravinetto, Amalia Hasnida and Koen Peeters Grietens
Universal aspirations and contextual decisions: The Essential Medicines List and Health Technology Assessment: Tineke Kleinhout-Vliek and Susi Geiger
Ecologies of pharmaceutical consumption: Sarah Wadmann
De/prescribing matters: Ecologies of prescribing and deprescribing in Science and Technology Studies: Lisa Lehner, Honja Hama, Igor Grabovac and Janina Kehr
Ecologies of resistance: The biosocial worlds of antibiotics: Joyce Sauann Lu and Omar Dewachi
Precision medicine and the reconfiguration of clinical practice and patienthood: Sarah Wadmann, Amalie Martinus Hauge, Anna Brueckner Johansen and Laura Emdal Navne
Beyond lay pharmacology: Fugitive, alternative, and pluralistic pharmacologies as collective practice: Magdalena Góralska, Anthony Rizk and Nayantara Sheoran Appleton
Pharmaceutical leakage: The porous interplay between legal and illegal opioid markets: Anne M. Lovell and Nancy D. Campbell
The food challenge to pharma: The unexplored potential of food drugs: Stephanie A. Nairn
Reflections: Pharmaceuticals and biotechnologies through STS lenses: Sergio Sismondo

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:elg:eebook:23545

Ordering information: This item can be ordered from
http://www.e-elgar.com

Access Statistics for this book

More books in Books from Edward Elgar Publishing
Bibliographic data for series maintained by Jack Sweeney ().